vasopharm's trauma compound VAS203 successfully completes clinical phase Ib study
vasopharm GmbH today announced the successful completion of its Series D financing round amounting to € 4.5 million (~ $ 6 million)
The investment was led by EMBL Ventures, Heidelberg, Germany. Additional investors participating in this round were Entrepreneurs Fund, London, UK, HeidelbergCapital Private Equity, Heidelberg, Germany as well as KfW, Frankfurt am Main, Germany.
The Series D financing round is primarily dedicated to an explorative European multicenter clinical phase IIa study exploring vasopharm’s compound VAS 203. All participating centers use routinely the technique of microdialysis in order to investigate acute pharmacodynamic effects of the compound during a three days lasting infusion. Intracranial pressure of the patients will also be monitored during this time.
VAS203 is an allosteric nitric oxide synthase inhibitor for the treatment of traumatic brain injury. It has demonstrated safety and tolerability in two clinical phase I studies with single and repetitive dosing schedules.back